Geneva, Aug. 29 -- International Clinical Trials Registry received information related to the study (NCT07133815) titled 'Evaluate the Long-term Efficacy and Safety of SHR-1918 in Patients With Homozygous Familial Hypercholesterolemia' on Aug. 14.

Study Type: Interventional

Study Design: Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Primary Sponsor: Beijing Suncadia Pharmaceuticals Co., Ltd

Condition: Homozygous Familial Hypercholesterolemia

Intervention: Drug: SHR-1918

Recruitment Status: Not recruiting

Phase: Phase 2

Date of First Enrollment: August 2025

Target Sample Size: 55

Countries of Recruitment: China

To know more, visit https://clinicaltria...